Company: CYTK
Filing Date: 2025-05-01
Form Type: 8-K
Source: 0000950170-25-061847
Chunk: 0

Company: CYTOKINETICS INC
Filing Date: 2025-05-01
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

Cytokinetics, Incorporated ("Cytokinetics") today announced that the U. S. Food and Drug Administration ("FDA") has extended the Prescription Drug User Fee Act ("PDUFA") action date for the New Drug Application ("NDA") for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy ("oHCM") to December 26, 2025. The FDA recently notified Cytokinetics that additional time is required to conduct a full review of the company’s proposed Risk Evaluation and Mitigation Strategy ("REMS").

Following pre-NDA discussions with FDA in which safety and risk mitigation were discussed, Cytokinetics submitted the NDA for aficamten in oHCM without an accompanying REMS, and the FDA accepted the NDA for filing. Recently, during the NDA review, the FDA requested that Cytokinetics submit a REMS, based on the inherent characteristics of aficamten, which the company provided. The submission of a REMS has now been determined by FDA to be a Major Amendment to the NDA resulting in a standard three-month extension to the original PDUFA action date. No additional clinical data or studies have been requested of Cytokinetics by FDA.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “ Act”). Cytokinetics claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but not limited to, statements, express or implied, relating to our receipt of regulatory approval by FDA or any other regulatory authority to enable our commercialization of aficamten in the United States or any other jurisdiction by the target PDUFA date or any other date, if ever, and statements regarding our expectation that aficamten will be approved with a differentiated label and REMS. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including FDA’s on-going review of our NDA for aficamten in obstructive hypertrophic cardiomyopathy. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission, particularly under the caption “ Risk Factors” in Cytokinetics’ Annual Report on Form 10-K for the year ended December 31, 2024.